Prof Nicole Lamanna - ASH 2019 - Maturing CLL clinical trial data
Dr. Nicole Lamanna, Associate Clinical Professor of haematological malignancies at Columbia University Medical Centre discusses the maturing CLL clinical trial data presented at ASH 2019.
Phenomenal 3 and 4 year results from trials of combinations of novel therapies raise new questions that require answering with more data: Are combinations of novel therapies better than sequential therapies? Which groups will benefit most from triplet, doublet combinations or sequential single agents? How novel next generation and 1st generation BTK inhibitors compare in long term head to head comparisons?
Dr Lamanna ASH update playlist youtube.com/playlist?list=P...
Prof Florence Cymbalista - ASH 2019 - The evolving treatment landscape
Prof Cymbalista of Avicenne Hospital, Paris, France discusses the changing treatment landscape in CLL and ASH hot topics: next generation BTK inhibitors, MRDu, new combinations to achieve this and treatment sequencing.
Dr Cymbalista ASH update playlist youtube.com/playlist?list=P...